X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6379) 6379
Publication (414) 414
Book Review (140) 140
Book Chapter (81) 81
Book / eBook (16) 16
Conference Proceeding (7) 7
Dissertation (5) 5
Magazine Article (5) 5
Data Set (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antithrombotic therapy (3868) 3868
humans (3835) 3835
index medicus (3038) 3038
male (1891) 1891
female (1745) 1745
atrial fibrillation (1541) 1541
warfarin (1430) 1430
anticoagulants (1428) 1428
aged (1423) 1423
cardiac & cardiovascular systems (1423) 1423
anticoagulants - therapeutic use (1392) 1392
risk factors (1265) 1265
stroke (1257) 1257
peripheral vascular disease (1159) 1159
prevention (1089) 1089
middle aged (1070) 1070
hematology (1068) 1068
aspirin (964) 964
thrombosis (944) 944
anticoagulation (859) 859
management (817) 817
risk (786) 786
atrial fibrillation - drug therapy (775) 775
thromboembolism (767) 767
treatment outcome (755) 755
anticoagulants - adverse effects (738) 738
anticoagulants - administration & dosage (737) 737
stroke - prevention & control (725) 725
aged, 80 and over (715) 715
pharmacology & pharmacy (711) 711
venous thromboembolism (711) 711
medicine, general & internal (670) 670
atrial-fibrillation (665) 665
fibrinolytic agents - therapeutic use (663) 663
animals (656) 656
atrial fibrillation - complications (656) 656
stroke prevention (576) 576
administration, oral (562) 562
risk-factors (556) 556
hemorrhage - chemically induced (523) 523
platelet aggregation inhibitors - therapeutic use (514) 514
molecular-weight heparin (495) 495
medicine & public health (494) 494
care and treatment (485) 485
adult (483) 483
warfarin - therapeutic use (480) 480
retrospective studies (473) 473
antithrombotic (470) 470
mortality (464) 464
stroke - etiology (458) 458
risk assessment (457) 457
surgery (456) 456
clopidogrel (433) 433
cardiology (432) 432
abridged index medicus (421) 421
drug therapy (420) 420
bleeding (414) 414
analysis (410) 410
deep-vein thrombosis (406) 406
dabigatran (400) 400
heparin (397) 397
antiplatelet therapy (388) 388
percutaneous coronary intervention (380) 380
rivaroxaban (376) 376
oral anticoagulation (372) 372
guidelines (358) 358
therapy (351) 351
oral anticoagulants (345) 345
myocardial-infarction (344) 344
ed american-college (334) 334
clinical neurology (332) 332
hemorrhage (332) 332
thromboembolism - prevention & control (327) 327
thrombosis - drug therapy (325) 325
aspirin - therapeutic use (316) 316
time factors (314) 314
internal medicine (311) 311
antithrombotic agents (309) 309
acute myocardial-infarction (307) 307
metaanalysis (306) 306
acute coronary syndromes (301) 301
fibrinolytic agents - adverse effects (300) 300
antithrombotics (299) 299
antithrombotic treatment (295) 295
cardiovascular (295) 295
incidence (291) 291
drug therapy, combination (285) 285
practice guidelines as topic (285) 285
cardiac arrhythmia (279) 279
unfractionated heparin (279) 279
prospective studies (278) 278
research (276) 276
patients (275) 275
health aspects (274) 274
warfarin - adverse effects (274) 274
dose-response relationship, drug (271) 271
platelet aggregation inhibitors - adverse effects (269) 269
thrombosis - prevention & control (269) 269
antiplatelet (262) 262
anticoagulant (260) 260
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5915) 5915
German (175) 175
French (98) 98
Spanish (98) 98
Russian (59) 59
Japanese (57) 57
Portuguese (19) 19
Polish (14) 14
Korean (10) 10
Czech (9) 9
Italian (9) 9
Hungarian (7) 7
Turkish (6) 6
Chinese (3) 3
Dutch (2) 2
Arabic (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e326S - e350S
Background: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or... 
VITAMIN-K-ANTAGONISTS | PERCUTANEOUS CORONARY INTERVENTION | PROSTHETIC HEART-VALVES | LOW-DOSE ASPIRIN | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ORAL ANTICOAGULANT-THERAPY | TRANEXAMIC ACID MOUTHWASH | NONVALVULAR ATRIAL-FIBRILLATION | INTERNATIONAL NORMALIZED RATIO | DRUG-ELUTING STENTS | CRITICAL CARE MEDICINE | Perioperative Care | United States | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Aspirin - pharmacokinetics | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - pharmacokinetics | Postoperative Complications - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Stents | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Heart Valve Prosthesis | Risk Factors | Atrial Fibrillation - complications | Evidence-Based Medicine | Atrial Fibrillation - blood | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Elective Surgical Procedures | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e669S - e690S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e1S - e23S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
Background: This article addresses the treatment of VTE disease. Methods: We generated strong (Grade 1) and weak (Grade 2) recommendations based on... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e737S - e801S
Background: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis.... 
INFERIOR VENA-CAVA | TISSUE-PLASMINOGEN-ACTIVATOR | ARTERIAL ISCHEMIC-STROKE | RESPIRATORY SYSTEM | CEREBRAL SINOVENOUS THROMBOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | SICKLE-CELL-DISEASE | HOMOZYGOUS PROTEIN-C | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Upper Extremity Deep Vein Thrombosis - blood | Child, Preschool | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Hemorrhage - prevention & control | Secondary Prevention | Heparin - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Cardiac Catheterization | Vitamin K - antagonists & inhibitors | Societies, Medical | Platelet Aggregation Inhibitors - administration & dosage | Renal Veins | Thrombosis - blood | Thrombosis - prevention & control | Child | Infant, Newborn | Platelet Aggregation Inhibitors - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Drug Administration Schedule | Risk Factors | Cooperative Behavior | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Interdisciplinary Communication | Thrombosis - etiology | Blood Coagulation Tests | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e576S - e600S
Background: Antithrombotic therapy in valvular disease is important to mitigate thromboembolism, but the hemorrhagic risk imposed must be considered. Methods:... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heart Valve Diseases - blood | Mitral Valve | Thrombosis - complications | Ductus Arteriosus, Patent - drug therapy | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Stroke - complications | Hemorrhage - prevention & control | Rheumatic Heart Disease - blood | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Ductus Arteriosus, Patent - blood | Thromboembolism - prevention & control | Aspirin - adverse effects | Heart Valve Diseases - complications | Fibrinolytic Agents - therapeutic use | Rheumatic Heart Disease - drug therapy | Rheumatic Heart Disease - complications | Aspirin - therapeutic use | Thromboembolism - drug therapy | Postoperative Complications - drug therapy | Thrombosis - blood | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Catheterization | Heart Atria | Heart Valve Prosthesis | Risk Factors | Ductus Arteriosus, Patent - complications | Combined Modality Therapy | Evidence-Based Medicine | Stroke - blood | Thromboembolism - blood | Heart Valve Diseases - drug therapy | Thrombosis - drug therapy | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e601S - e636S
Objectives: This article provides recommendations on the use of antithrombotic therapy in patients with stroke or transient ischemic attack (TIA). Methods: We... 
HIGH-RISK PATIENTS | TISSUE-PLASMINOGEN ACTIVATOR | CEREBRAL VENOUS THROMBOSIS | PATENT FORAMEN OVALE | RESPIRATORY SYSTEM | LONG-TERM SURVIVAL | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | ASPIRIN PLUS DIPYRIDAMOLE | NONVALVULAR ATRIAL-FIBRILLATION | EXTENDED-RELEASE DIPYRIDAMOLE | CRITICAL CARE MEDICINE | Recombinant Proteins - therapeutic use | United States | Humans | Heparin - therapeutic use | Tissue Plasminogen Activator - therapeutic use | Intracranial Thrombosis - prevention & control | Recombinant Proteins - adverse effects | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ischemic Attack, Transient - etiology | Aspirin - therapeutic use | Intracranial Thrombosis - drug therapy | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Ischemic Attack, Transient - drug therapy | Intermittent Pneumatic Compression Devices | Intracranial Thrombosis - blood | Combined Modality Therapy | Stroke - drug therapy | Evidence-Based Medicine | Stroke - blood | Intracranial Thrombosis - etiology | Thrombolytic Therapy | Ischemic Attack, Transient - blood | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
European Heart Journal, ISSN 0195-668X, 2012, Volume 33, Issue 20, pp. 2569 - 2619
Acute coronary syndromes Ischaemic heart disease | Reperfusion therapy | Primary percutaneous coronary intervention Antithrombotic therapy | Secondary prevention | Acute myocardial infarction | ST-segment elevation | Guidelines | CARDIAC & CARDIOVASCULAR SYSTEMS | BARE-METAL STENTS | Primary percutaneous coronary intervention | AMERICAN-HEART-ASSOCIATION | PERCUTANEOUS CORONARY INTERVENTION | INTRAAORTIC BALLOON COUNTERPULSATION | Antithrombotic therapy | LEFT-VENTRICULAR DYSFUNCTION | DUAL ANTIPLATELET THERAPY | SUSPECTED CARDIOGENIC-SHOCK | IN-HOSPITAL MORTALITY | Acute coronary syndromes | Ischaemic heart disease | CONVERTING-ENZYME INHIBITOR | DRUG-ELUTING STENTS | Antifibrinolytic Agents - therapeutic use | Humans | Heart Failure - physiopathology | Hyperglycemia - complications | Anxiety - prevention & control | Long-Term Care | Hemodynamics - physiology | Cardiomyopathies - etiology | Cardiotonic Agents - therapeutic use | Heart Failure - therapy | Myocardial Infarction - therapy | Out-of-Hospital Cardiac Arrest - therapy | Percutaneous Coronary Intervention - methods | Fibrinolytic Agents - therapeutic use | Electrocardiography | Cardiac Imaging Techniques - methods | Platelet Aggregation Inhibitors - therapeutic use | Dyspnea - prevention & control | Exercise Therapy - methods | Myocardial Infarction - diagnosis | Heart Failure - complications | Coronary Artery Bypass - methods | Arrhythmias, Cardiac - therapy | Pain - prevention & control | Risk Assessment | Risk Reduction Behavior | Time-to-Treatment | Emergency Treatment - methods | Biomedical Research - trends | Arrhythmias, Cardiac - etiology | Hospitalization | Out-of-Hospital Cardiac Arrest - diagnosis | Forecasting | Myocardial Reperfusion - methods | Cardiomyopathies - therapy | Myocardial Infarction - complications | Emergency Medical Services - organization & administration | General Practice - organization & administration | Hyperglycemia - therapy
Journal Article